SCA
CORT icon

Stonebridge Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Stonebridge Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed – – 1000
2022
Q3 		$0 Buy
+15
New +$401 ﹤0.01% 1015

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonebridge Capital Advisors's CORT Position: Q4 2022 in Review

Stonebridge Capital Advisors sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 15 shares.

Stonebridge Capital Advisors first reported a position in CORT in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 243 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

  • Stonebridge Capital Advisors reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 15 Corcept Therapeutics shares in Q4 2022.
  • Stonebridge Capital Advisors first reported a position in Corcept Therapeutics in Q3 2022 and held it in 1 quarter.
  • Stonebridge Capital Advisors's Corcept Therapeutics position peaked at $0 in Q3 2022.
  • 243 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.